碧迪医疗(BDX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BDX 碧迪医疗

未开盘 05-01 16:00:00 EDT

233.72

-0.88

-0.38%

盘后236.80

+3.08+1.32%

19:56 EDT

最高236.09	最低232.46	成交量272.16万
今开234.03	昨收234.60	日振幅1.55%
总市值675.22亿	流通市值673.57亿	总股本2.89亿
成交额6.37亿	换手率0.94%	流通股本2.88亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"BDX","market":"US","secType":"STK","nameCN":"碧迪医疗","latestPrice":233.72,"timestamp":1714593600000,"preClose":234.6,"halted":0,"volume":2721644,"hourTrading":{"tag":"盘后","latestPrice":236.8,"preClose":233.72,"latestTime":"19:56 EDT","volume":226729,"amount":52991476.58,"timestamp":1714607797883},"delay":0,"floatShares":288197021,"shares":288902232,"eps":4.206401,"marketStatus":"未开盘","marketStatusCode":0,"change":-0.88,"latestTime":"05-01 16:00:00 EDT","open":234.03,"high":236.09,"low":232.46,"amount":637146848.83348,"amplitude":0.015473,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":4.206401,"exchange":"NYSE","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1714636800000},"adr":0,"listingDate":-240782400000,"adjPreClose":234.6,"adrRate":0,"dividendRate":0.015745,"preHourTrading":{"tag":"盘前","latestPrice":233.11,"preClose":234.6,"latestTime":"09:28 EDT","volume":105,"amount":24489.79995,"timestamp":1714570136079},"postHourTrading":{"tag":"盘后","latestPrice":236.8,"preClose":233.72,"latestTime":"19:56 EDT","volume":226729,"amount":52991476.58,"timestamp":1714607797883},"volumeRatio":2.71749},"requestUrl":"/m/hq/s/BDX/wiki","defaultTab":"wiki","newsList":[{"id":"2427871310","title":"BUZZ-J&J 医疗技术部门销售额未达预期，医疗器械制造商业绩下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2427871310","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2427871310?lang=zh_cn&edition=full","pubTime":"2024-04-16 23:25","pubTimestamp":1713281142,"startTime":"0","endTime":"0","summary":"    4月16日 - ** 强生  医疗设备部门公布第一季度 ，销售额为78.2亿美元，低于华尔街预期的78.8亿美元，LSEG数据显示，医疗设备制造商股价下跌1%至3%。** 史赛克  下跌1%，Zimmer Biomet  下跌1.2%，美敦力  下跌1.4%，安捷伦  下跌2.4%，拜登迪金森  下跌0.9%，博士伦   下跌1.7%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2421185380","title":"Becton Dickinson 将增加国内注射器生产量","url":"https://stock-news.laohu8.com/highlight/detail?id=2421185380","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2421185380?lang=zh_cn&edition=full","pubTime":"2024-03-21 18:57","pubTimestamp":1711018664,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透社3月21日 - Becton Dickinson   公司周四表示，将增加国内医用注射器的产量。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2419941549","title":"多肽龙头翰宇药业出海再迎里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=2419941549","media":"中国科技新闻网","top":-1,"share":"https://www.laohu8.com/m/news/2419941549?lang=zh_cn&edition=full","pubTime":"2024-03-15 16:25","pubTimestamp":1710491152,"startTime":"0","endTime":"0","summary":"3月12日,全球化医疗器械创新龙头碧迪医疗到访翰宇药业,双方就“共同加速多肽药物国际化进程”的主题展开了深度交流,涉及翰宇药业利拉鲁肽注射剂产品美国市场商业化备货所需的注射笔供应保障,以及司美格鲁肽等未来GLP-1产品的合作规划等。事实上,正如翰宇药业董事长曾少贵所说,公司国际化战略布局已进入收获期,利拉鲁肽、司美格鲁肽、醋酸格拉替雷、西曲瑞克等产品的以美国为首的海外注册申报工作均顺利推进。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403151635258785da09&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403151635258785da09&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2408674300","title":"美国研究综述-Atlassian、Solo Brands、WEC Energy","url":"https://stock-news.laohu8.com/highlight/detail?id=2408674300","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2408674300?lang=zh_cn&edition=full","pubTime":"2024-02-02 17:31","pubTimestamp":1706866281,"startTime":"0","endTime":"0","summary":"    路透2月2日 - 华尔街证券分析师周五调整了对几家美国上市公司的评级和目标价，其中包括 Atlassian、Solo Brands 和 WEC Energy。要闻 * Atlassian Corp   ：Canaccord Genuity将目标价从240美元上调至260美元 * Euronet Worldwide Inc   ：Stephens将目标价从等权重上调至增持 * Roper Technologies Inc   ：Raymond James将目标价从572美元上调至620美元 * Solo Brands Inc   ：摩根大通将其评级从 \"增持 \"下调至 \"减持\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2408704639","title":"Becton Dickinson and Co 公布截至 12 月的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2408704639","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2408704639?lang=zh_cn&edition=full","pubTime":"2024-02-01 22:34","pubTimestamp":1706798047,"startTime":"0","endTime":"0","summary":"   * Becton Dickinson and Co   公布的截至12月底的季度调整后每股收益为2.68美元，低于去年同期的每股收益2.98美元。13 位分析师对该季度的平均预期为每股收益 2.40 美元。华尔街预期为每股收益 2.37 美元至 2.48 美元。* Becton Dickinson 公司公布的本季度每股收益为 96 美分。* 公司季度净收入为 2.81 亿美元。* 本季度 Becton Dickinson and Co 的股价下跌了 2.1%。华尔街对 Becton Dickinson and Co 的 12 个月目标价中位数为 280.00 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2408104687","title":"BUZZ-第一季度收入不及预期，Becton Dickinson 下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2408104687","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2408104687?lang=zh_cn&edition=full","pubTime":"2024-02-01 21:02","pubTimestamp":1706792526,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    2月1日 - ** 医疗设备制造商Becton Dickinson   股价盘前下跌2.6%，至232.69美元。** 公司季度营收47.1亿美元，低于分析师平均预期的47.3亿美元 ** BDX的生命科学部门（通过该部门销售诊断设备）第一季度销售额为12.9亿美元，低于分析师预期的13.1亿美元。 ** 该公司报告的第一季度 利润为 2.68 美元，低于分析师平均预期的 2.40 美元 - LSEG 数据** 截至上次收盘，股价在过去 12 个月下跌了 6","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2408811266","title":"手术器械强劲增长，百通迪金森上调 2024 年利润预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2408811266","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2408811266?lang=zh_cn&edition=full","pubTime":"2024-02-01 20:20","pubTimestamp":1706790043,"startTime":"0","endTime":"0","summary":"根据 LSEG 的数据，第一季度 Becton Dickinson 公司提供手术和重症监护设备的介入部门的销售额为 11.9 亿美元，高于预期的 11.8 亿美元。同时销售针头、注射器和其他此类医疗产品的 Becton Dickinson 公司，调整后每股利润为 2.68 美元，超过了分析师预计的每股 2.40 美元。经调整后，这家总部位于新泽西州的公司目前预计 2024 财年的每股收益将在 12.82 美元至 13.06 美元之间，高于此前预测的每股 12.70 美元至 13.00 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2407351133","title":"Becton Dickinson and Co   预计每股收益2.40美元 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2407351133","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2407351133?lang=zh_cn&edition=full","pubTime":"2024-01-30 21:48","pubTimestamp":1706622518,"startTime":"0","endTime":"0","summary":"   * Becton Dickinson and Co    将于2月1日公布截至2023年12月31日的财报，预计季度收入将有所增长。* 根据LSEG的数据，11位分析师的平均预期显示，这家总部位于新泽西州富兰克林湖区的公司的营收预计将从去年同期的45.9亿美元增长3.2%，达到47.32亿美元。   * LSEG 的分析师平均预期 Becton Dickinson and Co 每股收益为 2.40 美元。* 华尔街对 Becton Dickinson and Co 的 12 个月目标价中位数为 280.00 美元，高于其上次收盘价 237.85 美元。1月30日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2389028555","title":"更新版 1-美国食品和药物管理局批准百通公司的微创采血设备上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2389028555","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2389028555?lang=zh_cn&edition=full","pubTime":"2023-12-07 20:17","pubTimestamp":1701951472,"startTime":"0","endTime":"0","summary":"(全文增加细节)    路透12月7日 - Becton Dickinson   公司周四表示，美国食品和药物管理局(FDA) 批准了该公司的指刺采血设备，它可以为一些常用的实验室检验提供一种创伤较小的选择。该公司说，这种名为BD MiniDraw采集系统的设备可  通过 训练有素的医护人员从病人的手指采集 血液样本，而无需从 静脉采集。该公司说，这些许可包括为常用的化验项目采集血液样本，如血脂检测、诊断和监测从高血压到高胆固醇等各种慢性病的检测。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2388265495","title":"更新版 1-美国 FDA 称 BD 因兼容性问题召回输液泵","url":"https://stock-news.laohu8.com/highlight/detail?id=2388265495","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2388265495?lang=zh_cn&edition=full","pubTime":"2023-12-02 05:10","pubTimestamp":1701465049,"startTime":"0","endTime":"0","summary":"    路透12月1日 - 美国食品和药物管理局 周五称，由于与Cardinal Health公司  的Monoject注射器存在兼容性问题，Becton Dickinson公司  正在召回其Alaris输液泵。卫生监管机构 称，  ，Alaris输液泵经验证可与Monoject注射器一起使用。然而，Monoject 注射器的尺寸最近发生了变化，从 Covidien Monoject 改名为 Cardinal Health Monoject。美国食品及药物管理局说，这导致输液过多或过少，以及治疗延迟。该机构表示，目前已有 13 人受伤，但没有人死亡。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2384664203","title":"碧迪医疗2023财年实现净利润15.30亿美元，同比减少6.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2384664203","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2384664203?lang=zh_cn&edition=full","pubTime":"2023-11-18 00:20","pubTimestamp":1700238049,"startTime":"0","endTime":"0","summary":"9月30日，碧迪医疗公布财报，公告显示公司2023财年净利润为15.30亿美元，同比减少6.42%；其中营业收入为193.72亿美元，同比增加2.66%，每股基本收益为4.97美元。机构评级：截至2023年9月30日，当前有13家机构对碧迪医疗目标价做出预测，其中目标均价为282.77美元，其中最低目标价为240.00美元，最高目标价为310.00美元。碧迪医疗业务占总业务量的近一半，碧迪生命科学业务和 碧迪介入业务占其余部分。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20231118002055828279aa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20231118002055828279aa&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2383701816","title":"碧迪医疗助力杭州协合医疗全球化战略布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2383701816","media":"中国经济网","top":-1,"share":"https://www.laohu8.com/m/news/2383701816?lang=zh_cn&edition=full","pubTime":"2023-11-13 14:59","pubTimestamp":1699858768,"startTime":"0","endTime":"0","summary":"11月9日，杭州协合医疗与碧迪医疗制药系统在第六届进博会上达成战略合作意向，内容包括意向金额达3亿元的透明质酸预灌封注射器产品，预计将为数千万求美用户提供更优质、更安全的体验。杭州协合医疗总经理孙伟庆、碧迪医疗大中华区战略创新与商业卓越副总裁姜崴出席了仪式。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20231113150543826e75ee&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20231113150543826e75ee&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2382278537","title":"直击进博｜碧迪医疗全球高级副总裁邓建民：创新医疗器械的生产运营成本有望进一步降低","url":"https://stock-news.laohu8.com/highlight/detail?id=2382278537","media":"新浪财经","top":-1,"share":"https://www.laohu8.com/m/news/2382278537?lang=zh_cn&edition=full","pubTime":"2023-11-10 17:44","pubTimestamp":1699609440,"startTime":"0","endTime":"0","summary":"　　11月10日，碧迪医疗全球高级副总裁、大中华区总经理邓建民第六届进博会医疗器械专业委员会高端医疗器械开放创新高峰论坛上表示，其对中国市场和本土化创新充满信心，不管是起跑、加速还是冲刺阶段，中国创新都跑出了‘中国速度’。与此同时，借助全球创新管线与研发能力基础，加上本土化创新的推进，创新医疗器械的生产运营成本有望进一步降低，进而造福更多患者。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2023-11-10/doc-imzucprn3422100.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2023-11-10/doc-imzucprn3422100.shtml","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bd.com","stockEarnings":[{"period":"1week","weight":-0.0005},{"period":"1month","weight":-0.0423},{"period":"3month","weight":-0.0356},{"period":"6month","weight":-0.0973},{"period":"1year","weight":-0.114},{"period":"ytd","weight":-0.0415}],"compareEarnings":[{"period":"1week","weight":-0.01},{"period":"1month","weight":-0.0418},{"period":"3month","weight":0.0228},{"period":"6month","weight":0.1511},{"period":"1year","weight":0.2179},{"period":"ytd","weight":0.0527}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"碧迪医疗器械有限公司于1906年11月根据新泽西州法律注册成立。该公司是一家全球性的医疗技术公司，从事医疗机构、医生、生命科学研究人员、临床实验室、制药行业和公众使用的各种医疗用品、设备、实验室设备和诊断产品的开发、制造和销售。公司提供客户解决方案，重点是改善药物管理和患者安全；支持感染预防实践；配备手术和介入手术；改进药物输送；协助麻醉护理；加强传染病和癌症的诊断；促进细胞研究和应用；支持糖尿病的管理。","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.038615},{"month":2,"riseRate":0.5,"avgChangeRate":0.004773},{"month":3,"riseRate":0.568182,"avgChangeRate":-0.003408},{"month":4,"riseRate":0.511111,"avgChangeRate":0.007201},{"month":5,"riseRate":0.488889,"avgChangeRate":0.013721},{"month":6,"riseRate":0.613636,"avgChangeRate":0.006914},{"month":7,"riseRate":0.568182,"avgChangeRate":-0.001683},{"month":8,"riseRate":0.636364,"avgChangeRate":0.008515},{"month":9,"riseRate":0.386364,"avgChangeRate":-0.001838},{"month":10,"riseRate":0.5,"avgChangeRate":0.007697},{"month":11,"riseRate":0.659091,"avgChangeRate":0.022341},{"month":12,"riseRate":0.681818,"avgChangeRate":0.02022}],"exchange":"NYSE","name":"碧迪医疗","nameEN":"Becton Dickinson"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"碧迪医疗(BDX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供碧迪医疗(BDX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"碧迪医疗,BDX,碧迪医疗股票,碧迪医疗股票老虎,碧迪医疗股票老虎国际,碧迪医疗行情,碧迪医疗股票行情,碧迪医疗股价,碧迪医疗股市,碧迪医疗股票价格,碧迪医疗股票交易,碧迪医疗股票购买,碧迪医疗股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"碧迪医疗(BDX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供碧迪医疗(BDX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}